Momenta Pharmaceuticals (Momenta Pharmaceuticals) LT-Debt-to-Total-Asset : 0.06 (As of Jun. 2020)

View and export this data going back to 2004. Start your Free Trial

What is Momenta Pharmaceuticals LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Momenta Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Jun. 2020 was 0.06.

Momenta Pharmaceuticals's long-term debt to total assets ratio declined from Jun. 2019 (0.17) to Jun. 2020 (0.06). It may suggest that Momenta Pharmaceuticals is progressively becoming less dependent on debt to grow their business.

Momenta Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

The historical data trend for Momenta Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Momenta Pharmaceuticals LT-Debt-to-Total-Asset Chart

Momenta Pharmaceuticals Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.06

Momenta Pharmaceuticals Quarterly Data
	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.17	0.09	0.06	0.06	0.06

Momenta Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Momenta Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2019 is calculated as

LT Debt to Total Assets (A: Dec. 2019 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2019 )	/	Total Assets (A: Dec. 2019 )
	=	34.306	/	618.365
	=	0.06

Momenta Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2020 is calculated as

LT Debt to Total Assets (Q: Jun. 2020 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2020 )	/	Total Assets (Q: Jun. 2020 )
	=	31.354	/	523.279
	=	0.06

Momenta Pharmaceuticals (NAS:MNTA) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Momenta Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Momenta Pharmaceuticals's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Momenta Pharmaceuticals (Momenta Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Momenta Pharmaceuticals Inc (NAS:MNTA) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

301 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.momentapharma.com

Momenta is a biotechnology company focused on the characterization and development of innovative drugs in autoimmune diseases. Its legacy business includes complex generic versions of MS drug Copaxone and anticoagulant Lovenox, and it receives royalties for these products through a partnership with Novartis. While a biosimilar version of Eylea is in the pipeline, Momenta terminated future development in generics/biosimilars in 2018. Several innovative drugs, including nipocalimab, M254, and M230, are in development to treat rare autoimmune diseases.

Executives

Bruce Downey	director
Alejandra Carvajal	officer: Chief Legal Officer	C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, 5TH FLOOR, CAMBRIDGE MA 02139
Jose-carlos Gutierrez-ramos	director	C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Georges Gemayel	director	550 HILLS DRIVE, BEDMINSTER NJ 07921
Elizabeth Stoner	director	C/O MOMENTA PHARMACEUTICALS, INC. 675 WEST KENDALL STREET CAMBRIDGE MA 02142
Santiago Arroyo	officer: SVP, Chief Medical Officer	C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Young Kwon	officer: Chief Financial & Bus. Officer	C/O MOMENTA PHARMACEUTICALS INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Ian Fier	officer: Chief Mfg and Program Officer	C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142
Steven C Gilman	director	110 HARTWELL AVENUE, LEXINGTON MA 02421
Jo Ann Beltramello	officer: Chief HR and Inf. Officer	C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142
Jane F Barlow	director	6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Anthony M. Manning	officer: Chief Scientific Officer	C/O PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Donna Roy Grogan	director	1133 OLD QUEEN ANNE ROAD, CHATHAM MA 02633
Agnieszka Cieplinska	officer: Chief Accounting Officer (PAO)	C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142
Craig A Wheeler	director, officer: President & CEO